Beta Delta

Genentech’s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans

ohad.. any reasons you can think of as to why dna is delaying in announcing a pivotal trial. Is it FDA related? surely the data confirms that tras-dm1 works far better than herceptin unconjugated, and the need to get new drugs deeper into clinical trials and approved for this patient pop/MBC. the recent data for the combo of tykerb/xeloda is not overwhelming. surely this appears to be a slam dunk to enter a pivotal trial sooner than later .